Why are most Europeans opposed to GMOs? Factors explaining rejection in France and Europe
Full Text
Reprint PDF

Keywords

agriculture
acceptance
opposition movement
risk/benefit balance
risk perception

How to Cite

1.
Bonny S. Why are most Europeans opposed to GMOs? Factors explaining rejection in France and Europe. Electron. J. Biotechnol. [Internet]. 2003 Apr. 15 [cited 2024 Dec. 22];6(1):0-. Available from: https://www.ejbiotechnology.info/index.php/ejbiotechnology/article/view/v6n1-4

Abstract

A strong movement of opposition to GMOs developed in the late 1990s in many countries, especially in Europe, although these technologies were presented from the outset as highly promising and their advantages were often highlighted. How can this rejection be explained? The aim of this paper is to answer that question through the case of France, which is fairly representative in this respect of various European countries, even if the opposition movement is here particularly strong. One examines various factors, actors and processes that have led to such strong opposition to GMOs that at this stage their development in Europe has almost totally been halted. In the first part of the article we recall the results of several recent surveys, showing the level of acceptance or refusal of genetic engineering in several countries. We then examine important factors of rejection: the focus on potential risks of GMOs and the extensive publicity given to them, coupled with the inadequacy of answers to these diverse criticisms, and a drawing up of an unfavorable risk-benefit balance. Lastly, we point out that various fears and objections to the evolution of agriculture and to the functioning of society (i.e. limited trust in institutions and firms) appear to be crystallized around GMOs.

Full Text
Reprint PDF

Upon acceptance of an article by the journal, authors will be asked to transfer the copyright to Electronic Journal of Biotechnology, which is committed to maintain the electronic access to the journal and to administer a policy of fair control and ensure the widest possible dissemination of the information. The author can use the article for academic purposes, stating clearly the following: "Published in Electronic Journal of Biotechnology at DOI:10.2225/volXX-issueX-fulltext-XX".

The Copyright Transfer Agreement must be submitted as a signed scanned copy to biotec@ucv.cl. All authors must send a copy of this document.